Moreover, TZ was found to disrupt signaling pathways downstream of PI3K, including Akt, PDK1, and mTOR, in ovarian tumor progression via vascular endothelial growth factor receptor 2 (VEGFR-2). This evidence concerns the gene KDR and ovarian neoplasm.